Relative Risk Reduction News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Relative risk reduction. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Relative Risk Reduction Today - Breaking & Trending Today

Pfizer is sued by Texas over COVID-19 vaccine claims

Pfizer has been sued by Texas Attorney General Ken Paxton, who on Thursday accused the drugmaker of misrepresenting the efficacy of its widely-used COVID-19 vaccine. In a complaint filed in a Lubbock County state court, Paxton said it was misleading for Pfizer to claim its vaccine was 95% effective because it offered a "relative risk reduction" for people to who took it. Paxton said the claim was based on only two months of clinical trial data, and vaccine recipients' "absolute risk reduction" showed that the vaccine was just 0.85% effective. ....

Lubbock County , United States , New York , Jonathan Stempel , Chizu Nomiyama , Ken Paxton , Texas Attorney General Ken Paxton , New York Based Pfizer , Relative Risk Reduction , Vaccine Recipients , Absolute Risk Reduction , Texas Attorney General , Vaccine Mandates ,

INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in MACE related outcomes as early as approximately three months in patients at high risk for cardiovascular events INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 12, 2023 (GLOBE NEWSWIRE) Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today ....

United States , Rahul Aggarwal , Craig Granowitz , Exchange Commission , Lexicon Pharmaceuticals , Lexicon Pharmaceuticals Inc , Drug Administration , Science Session Of The American Heart Association , American Heart Association , Scientific Sessions , Concomitant Use , Insulin Secretagogues , Mycotic Infections , Glucose Test , Adverse Reactions , Specific Populations , Late Breaking Science Session , New England Journal , Chronic Kidney Disease , Investor Inquiries , Relative Risk Reduction , Heart Failure , Lexicon Pharmaceuticals , Cardiovascular Events , American Heart Association , Post Hoc Analysis ,